Clinical Trial

Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)

Study acronym: MRI
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 28, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy and safety of Gadopiclenol, an FDA-approved contrast agent, for visualizing pituitary lesions on MR images by comparing with the comparator, Gadobutrol, a clinically widely used contrast agent. The study is double-blinded, so neither the participants nor the researchers know which contrast agent is being used during each scan to avoid the bias of results.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-20; most recent amendment 2026-04-24.
Status change: Not Yet Recruiting → Recruiting 2025-04-11
Trial Details
NCT Number NCT06846853
Lead Sponsor UConn Health
Conditions Contrast Enhanced Images vs. Non-contrast Images, Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images
Enrollment 10 participants
Start Date 2025-03-25
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-28